Nobody likes the grammar police. Patent lawyers, unfortunately, may be the exception.
In Enanta Pharmaceuticals, Inc. v. Pfizer Inc. No. 2025-1427 (Fed. Cir. June 23, 2026), one character did a lot of damage. The difference between C2 and C1 cost Enanta the priority date of its provisional application—and led the Federal Circuit to affirm that








